Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nogapendekin Alfa Inbakicept→

Nogapendekin Alfa Inbakicept Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Interleukin-15 superagonist complexIL-15 receptor agonist immunotherapy
Mechanism of action
A recombinant IL-15 superagonist complex that activates IL-15 receptor signalling on natural killer cells and CD8-positive T cells, promoting their proliferation, activation and antitumour immune responses within the bladder.
Indications / reported uses
  • In combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours, under the US ANKTIVA indication; for intravesical use only

Sources: US DailyMed — ANKTIVA (nogapendekin alfa inbakicept) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nogapendekin Alfa Inbakicept Environmental Risk Assessment (ERA) (the Nogapendekin Alfa Inbakicept ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.